





Dihydroartémisinine + pipéraqouine

Statut de médicament essentiel 

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

		EMLc	Codes ATC: P01BF05
Indication	Malaria due to Plasmodium falciparum	Code ICD11: 1F40	
Type de médicament	Chemical agent		
Type de liste	Liste de base (EML) (EMLc)		
Formulations	Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate) (EMLc) ; 40 mg + 320 mg (phosphate) (EMLc) Oral > Solid > tablet: 40 mg + 320 mg (phosphate) ; 20 mg + 160 mg (phosphate) ; 60 mg + 480 (phosphate) ; 80 mg + 640 mg (phosphate)		
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2025 (TRS 1064)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 		
Wikipédia	Dihydroartémisinine + pipéraqouine 		
DrugBank	Artemimol  , Pipéraqouine 		

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of two new strengths of tablets (60mg + 480 mg and 80 mg + 840 mg) on the EML and EMLc; - the addition of two new strengths of dispersible tablets (20 mg + 160 mg and 40 mg + 320 mg) on the EMLc; - removal of the weight restriction, in recognition that use should be in line with recommendations with WHO guidelines; - to update the listing to include reference to the phosphate salt of pipéraqouine in the formulation description instead of the medicine name.

